课题基金 / 基金详情

RFA-IP-22-004, Evaluating respiratory virus vaccine effectiveness in a large, diverse healthcare system

RFA-IP-22-004, Evaluating respiratory virus vaccine effectiveness in a large, diverse healthcare system
RFA-IP-22-004,在大型、多样化的医疗保健系统中评估呼吸道病毒疫苗的有效性
批准号:
10703261
负责人:
RICHARD K ZIMMERMAN
金额:
$190.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-30 至 2027-09-30
关键词:

项目摘要

项目成果

RICHARD K ZIMMERMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract – Component A We are applying for RFA components A and D. This abstract refers to Component A. Influenza/pneumonia comprise the 9th and COVID-19 the 3rd leading cause of death in the U.S., with the pandemic entering its 3rd year. Vaccine effectiveness (VE) estimates vary by host factors, viral clade, match to circulating virus, time since vaccination (i.e., waning) and specific vaccine characteristics. PittVax and collaborators have been integral to the US Flu VE Network for 12 years, contributing to influ- enza and COVID-19 VE estimates. Among the current 7 Network sites, PittVax ranks #2 in enrollments, #2 in bloodspot collections, and #1 in follow-up survey completion, while exceeding enrollment goals. PittVax has published >300 peer-reviewed articles in the field. We propose a test-negative case-control design (TND) study among UPMC and federally qualified health center (FQHC) outpatients to determine influenza, COVID-19 and possibly, other respiratory virus VE. Our specific aims are: 1) Determine VE against laboratory-confirmed, medically-attended, acute respiratory in- fections among 1000-1200 outpatients during the influenza season in age groups: 6 mos-18 yrs, 19-49 yrs, and ≥50 yrs, using test negative design in onsite enrollment during respiratory season plus remote enroll- ment outside of influenza season (another 400-900 if COVID-19 persists); 2) provide genetic sequencing on selected specimens for biweekly trends in clade; and 3) determine the annual, population-based burden of influenza and COVID-19 for Allegheny County (Pittsburgh) from the UPMC Health Plan. For determining prior infection for SARS-CoV-2 (e.g., N protein) in the highest proportion of participants, we propose finger- stick bloodspots, supplemented by sera on a subset, for more in-depth studies. The Williams lab, using vali- dated 96-well plate instruments for RT-PCR, which analyzed >10,000 specimens over the last 6 years for influenza, SARS-CoV-2 and other respiratory viruses, will determine presence of infecting viruses. The ex- perienced Harrison lab will perform viral genomic sequencing. We will obtain immunization records from the state’s registry and from UPMC’s and the FQHC’s electronic records. UPMC Health Plan is the largest insurer in Allegheny County and at UPMC in 2021-22, >126,000 county residents were clinically tested for SARS-CoV-2. Annually, UPMC records >5.6 million outpatient visits. Over 1.4 million UPMC acute care visits a year are assessed at Emergency Departments (EDs) and Urgent Care clinics through a common structure and e-record with 305,751 ED visits in 2021 among our four recruiting EDs. UPMC has been rated one of the most wired health systems for 23 years. To address health equity, we add FQHC offices serving mostly persons of color and leadership from the Black Equity Coalition to our multidisciplinary team to assist with culturally competent script/survey development, inclusion of social deter- minants of health data and dissemination of findings with a health equity perspective.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RFA-IP-22-004, Evaluating respiratory virus vaccine effectiveness in a large, diverse healthcare system
Outpatient VE for seasonal flu, pandemic flu and RSV in a large, diverse network
Outpatient VE for seasonal flu, pandemic flu and RSV in a large, diverse network
Flu vaccine effectiveness in those hospitalized in a large diverse health system
国内基金
海外基金
五溪流域民族医药康养IP价值生成机制与品牌生态构建研究
  • 批准号:
    2026JJ80530
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    张卓
  • 依托单位:
IP3R/GRP75/VDAC1介导内质网应激—线粒体氧化应激调控慢传输型便秘ICC凋亡的机制及生血通便颗粒的干预作用
基于内质网-线粒体互作的电针抑制骨关节炎软骨细胞铁死亡的机制研究:聚焦IRE1α/IP3R-MCU信号轴与钙稳态
  • 批准号:
    2026JJ50328
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    刘静
  • 依托单位:
湖湘非遗IP的数字化建构与文旅价值链融合机制研究申报书
  • 批准号:
    2026JJ81201
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    陶喆
  • 依托单位: